Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K, Myojin Y, Monge C, Xie C, Hrones DM, Wood BJ, Levy EB, Kleiner D, Figg WD, Steinberg SM, Redd B, Greten TF. Coffman-D'Annibale K, et al. Among authors: monge c. J Immunother Cancer. 2024 Jan 6;12(1):e008079. doi: 10.1136/jitc-2023-008079. J Immunother Cancer. 2024. PMID: 38184304 Free PMC article. Clinical Trial.
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
Monge C, Pehrsson EC, Xie C, Duffy AG, Mabry D, Wood BJ, Kleiner DE, Steinberg SM, Figg WD, Redd B, Budhu A, Wang S, Tandon M, Ma L, Wei Wang X, Greten TF. Monge C, et al. Oncologist. 2022 Mar 11;27(3):e273-e285. doi: 10.1093/oncolo/oyab073. Oncologist. 2022. PMID: 35274717 Free PMC article. Clinical Trial.
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, Hewitt SM, Kleiner DE, Steinberg SM, Figg WD, Redd B, Homan P, Cam M, Ruf B, Duffy AG, Greten TF. Monge C, et al. J Immunother Cancer. 2023 Feb;11(2):e005640. doi: 10.1136/jitc-2022-005640. J Immunother Cancer. 2023. PMID: 36754451 Free PMC article. Clinical Trial.
The current landscape of therapies for hepatocellular carcinoma.
Coffman-D'Annibale K, Xie C, Hrones DM, Ghabra S, Greten TF, Monge C. Coffman-D'Annibale K, et al. Among authors: monge c. Carcinogenesis. 2023 Oct 20;44(7):537-548. doi: 10.1093/carcin/bgad052. Carcinogenesis. 2023. PMID: 37428789 Free PMC article. Review.
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
Monge C, Xie C, Myojin Y, Coffman-D'Annibale KL, Hrones D, Brar G, Wang S, Budhu A, Figg WD, Cam M, Finney R, Levy EB, Kleiner DE, Steinberg SM, Wang XW, Redd B, Wood BJ, Greten TF. Monge C, et al. Cancer Med. 2024 Feb;13(3):e6912. doi: 10.1002/cam4.6912. Epub 2024 Jan 11. Cancer Med. 2024. PMID: 38205877 Free PMC article.
188 results